Skip to main content

Jack Slevin

Stock Analyst at Jefferies

Total Price Targets
5
Stocks Covered
5
Sectors
Healthcare
Most Recent
Mar 9, 2026

Notable Calls (Last 12 Months)

Most Bullish

  • PRVA+28.5%
    Privia Health Group, Inc.
    $32.00 targetFeb 26, 2026
  • USPH+26.6%
    U.S. Physical Therapy, Inc.
    $102.00 targetMar 9, 2026
  • CCRN+16.0%
    Cross Country Healthcare, Inc.
    $8.65 targetDec 4, 2025

Most Bearish

  • AGL+0.5%
    Agilon Health, Inc.
    $27.50 targetAug 15, 2025
  • CCRN+16.0%
    Cross Country Healthcare, Inc.
    $8.65 targetDec 4, 2025
  • USPH+26.6%
    U.S. Physical Therapy, Inc.
    $102.00 targetMar 9, 2026

Stocks Covered by Jack Slevin

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
USPHU.S. Physical Therapy, Inc.$102.00$72.03+41.6%1Mar 9, 2026
PRVAPrivia Health Group, Inc.$32.00$24.76+29.2%1Feb 26, 2026
CCRNCross Country Healthcare, Inc.$8.65$10.21-15.3%1Dec 4, 2025
AGLAgilon Health, Inc.$27.50$29.23-5.9%1Aug 15, 2025
MDPediatrix Medical Group, Inc.$14.00$22.80-38.6%1Sep 26, 2024

Recent Activity

  • Mar 9, 2026— Set$102.00price target onUSPH(U.S. Physical Therapy, Inc.)
  • Feb 26, 2026— Set$32.00price target onPRVA(Privia Health Group, Inc.)
  • Dec 4, 2025— Set$8.65price target onCCRN(Cross Country Healthcare, Inc.)
  • Aug 15, 2025— Set$27.50price target onAGL(Agilon Health, Inc.)
  • Sep 26, 2024— Set$14.00price target onMD(Pediatrix Medical Group, Inc.)

Frequently Asked Questions

Who is Jack Slevin?

Jack Slevin is a stock analyst at Jefferies covering 5 stocks primarily in Healthcare. They have issued 5 price targets since Sep 26, 2024.

What stocks does Jack Slevin cover?

Jack Slevin currently covers 5 stocks, including USPH, PRVA, CCRN, AGL, MD.

What is Jack Slevin's latest price target?

Jack Slevin's most recent price target was $102.00 on USPH (U.S. Physical Therapy, Inc.), set on Mar 9, 2026.

What is Jack Slevin's highest price target?

Jack Slevin's highest issued price target is $102.00 on USPH, set on Mar 9, 2026.

Coverage based on publicly published price targets. Not investment advice.